In the field of cancer immunotherapy, PD-1 / PD-L1 is undoubtedly the most popular target. In view of the key role of PD-L1 in controlling T cell activity, PD-L1 on the surface of cancer cells has become the focus of immunotherapy. Scientists screened the whole genome crispr-cas9 and found that cmtm6 is a key regulator of PD-L1 in a wide range of cancer cells.

Cmtm6 and PD-L1 co localize on plasma membrane and endosomes, the study said. Here, cmtm6 can prevent PD-L1 from becoming the target of lysosomal mediated degradation.

These findings not only further understand the mechanism of PD-L1 checkpoint, but also reveal a new target of cancer immunotherapy.

More cases

Case 1: the role of CRISPR genomic screening signaling pathway research

Case 2: the role of CRISPR genome screening in the discovery of new tumor immune regulatory factors

Case 3: discovery of key target genes of tumor immunotherapy through CRISPR high-throughput genome screening